Welcome to our dedicated page for Cocrystal Pharma SEC filings (Ticker: COCP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides organized access to Cocrystal Pharma, Inc. (Nasdaq: COCP) SEC filings, allowing readers to review the company’s official regulatory disclosures alongside AI-generated highlights. Cocrystal is a clinical-stage biotechnology company developing structure-based antiviral therapeutics targeting influenza viruses, coronaviruses, noroviruses and hepatitis C viruses, and its filings describe how these programs are financed and advanced.
Here you can review current reports on Form 8-K, which Cocrystal uses to disclose material events. Recent 8-K filings have reported quarterly financial results, FDA Investigational New Drug (IND) clearance and a Study May Proceed Letter for a Phase 1b human challenge study with CDI-988, an oral broad-spectrum 3CL protease inhibitor for norovirus, as well as an NIH Small Business Innovation Research (SBIR) Phase I award supporting an influenza A/B polymerase complex program. Other 8-Ks detail registered direct offerings and private placements of common stock and warrants, including insider participation and the terms of securities purchase agreements.
The page also links to registration statements such as the Form S-1 filed in 2025, which registers the resale of shares issuable upon exercise of outstanding warrants originally issued in a private placement concurrent with a registered direct offering. These documents outline the company’s capital structure, risk factors and use of proceeds related to COCP shares and associated warrants.
Stock Titan’s tools surface AI-powered summaries of lengthy filings, helping users quickly understand key points from 8-Ks, S-1 registration statements and other reports without reading every page. Investors can also track disclosures related to equity financings, warrant terms and listing information for COCP on The Nasdaq Capital Market. This filings hub is intended as a starting point for deeper review of Cocrystal’s official SEC documents on EDGAR.
Cocrystal Pharma, Inc. filed a current report describing new clinical and scientific visibility for its oral norovirus drug candidate CDI-988. The company presented mechanism-of-action and early clinical data at the ICAR 2026 antiviral research conference, highlighting completed Phase 1 results and an ongoing Phase 1b human challenge study.
CDI-988, a first oral direct-acting 3CL protease inhibitor for norovirus, was generally safe and well tolerated in a randomized, double-blind, placebo-controlled Phase 1 trial in healthy adults at doses up to 1,200 mg, with no serious adverse events. The Phase 1b challenge trial at Emory University and the University of North Carolina plans to enroll up to 40 adults, with a fully enrolled initial cohort establishing infectivity of the norovirus GII.2 inoculum before prevention and treatment cohorts receiving 1,200 mg twice daily for five days.
The company notes that CDI-988 has U.S. FDA Fast Track designation for treatment and prophylaxis of norovirus infection, a disease with substantial global burden and no approved vaccines or therapies.
Cocrystal Pharma, Inc. files a shelf registration to offer up to $150,000,000 of common stock, preferred stock, warrants and units.
The shelf permits sales from time to time and also includes unsold securities from a prior registration statement; the company states net proceeds will be used for working capital and other general corporate purposes.
Cocrystal Pharma reports that the U.S. Food and Drug Administration has granted Fast Track designation to CDI-988, its oral, direct-acting protease inhibitor for treatment and prophylaxis of norovirus infection. Fast Track status is intended to accelerate development and regulatory review for serious conditions with unmet medical needs.
CDI-988 targets a highly conserved region of noroviruses and other 3CL viral proteases, and is being studied in an ongoing Phase 1b randomized, double-blind, placebo-controlled norovirus challenge trial in up to 40 healthy adults at Emory University School of Medicine. The study’s primary endpoint is reduction in clinical symptoms, with secondary endpoints including viral shedding, disease severity, safety, and pharmacokinetics.
Cocrystal Pharma reported a 2025 net loss of $8.8 million, or $0.78 per share, improving from a $17.5 million loss in 2024. Research and development expenses fell to $5.1 million from $12.5 million, and general and administrative costs declined to $4.0 million from $5.3 million.
The Company ended 2025 with $7.7 million in unrestricted cash, $5.9 million of working capital and 11.3 million common shares outstanding. Cocrystal advanced its antiviral pipeline, with a Phase 1b human challenge study of norovirus candidate CDI-988 underway and influenza A candidate CC-42344 completing an initial Phase 2a study with favorable safety.
Cocrystal Pharma, Inc. reported that board member Dr. Anthony Japour passed away on March 10, 2026. The company filed this current report to formally disclose his death as a change in its board of directors. The filing is signed by Co-Chief Executive Officer and Chief Financial Officer James Martin.
Cocrystal Pharma reported that the first subjects have been dosed in its Phase 1b norovirus human challenge study of CDI-988 at Emory University School of Medicine. The randomized, double-blind, placebo-controlled trial will enroll up to 40 healthy adults ages 18–49 who are intentionally infected with the GII.2 norovirus strain.
CDI-988 is a direct-acting, oral antiviral designed to inhibit a highly conserved region of the viral 3CL protease across known norovirus strains. The primary goal of the study is to assess efficacy versus placebo in reducing clinical symptoms, with secondary measures including viral shedding, disease severity, safety and pharmacokinetics. CDI-988 previously showed favorable safety and tolerability in a Phase 1 study up to a 1200 mg dose.
The company highlights norovirus as a major unmet medical need, with an estimated 685 million global cases and a $60 billion annual economic burden, and notes there are currently no approved treatments or vaccines for prevention or treatment.
Cocrystal Pharma director and 10% owner Phillip Frost, M.D., reported an indirect open-market purchase of 20,000 shares of Cocrystal Pharma common stock. The shares were bought on February 24, 2026 at a weighted average price of $0.9976 per share in trades ranging from $0.98 to $1.00.
The purchased shares are held by Frost Gamma Investments Trust, an entity associated with Dr. Frost, which now holds 1,908,551 shares indirectly. Dr. Frost also holds 27,100 shares directly, including shares issuable upon vesting of restricted stock units, and disclaims beneficial ownership of the trust’s holdings except for any pecuniary interest.
Cocrystal Pharma filed a Form 8-K to share a press release about its oral norovirus protease inhibitor CDI-988. Initial progress from a Phase 1b norovirus challenge study will be presented at the 39th International Conference on Antiviral Research (ICAR2026) in Prague.
CDI-988 is described as the first oral antiviral drug candidate under development for prevention and treatment of acute norovirus gastroenteritis and is designed as a pan-viral 3CL protease inhibitor with potential activity against both noroviruses and coronaviruses. The company highlights the lack of approved antiviral therapies or vaccines for norovirus, which causes an estimated 200,000 deaths worldwide each year and significant economic burden, underscoring the potential medical need targeted by this program.